Eur Urol: Long-term outcomes of Pembrolizumab plus Olaparib in the treatment of patients with metastatic castration-resistant prostate cancer

Pembrolizumab and olaparib have shown single-agent activity
in previously treated patients with metastatic tendency resistant prostate cancer (mCRPC).

Recently, researchers from the United States published an article in Eur Urol evaluating the efficacy and safety of Pembrolizumab combined with olaparib in patients with mCRPC
.

The study included Cohort A patients in the Phase 1b/2 KEYNOTE-365 study who were mCRPC patients who had not been selected molecularly but were treated with docetaxel and whose disease progressed
within 6 months of screening.

The intervention in the study was Pembrolizumab 200 mg intravenously every 3 weeks, plus olaparib 400 mg capsules or 300 mg tablets twice
a day.

Of the 104 enrolled patients, 102 were treated
.

Treatment-related side effect events

In summary, the safety of Pembrolizumab in combination with olaparib is consistent with the safety of individual drugs and exhibits antitumor activity
in patients with mCRPC who have previously been treated, have not been molecularly selected, and who have been pre-treated with docetaxel.

Original Source:

Evan Y Yu， Josep M Piulats， Gwenaelle Gravis et al.